United Therapeutics (UTHR) CEO trades shares under 10b5-1 stock plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
United Therapeutics Corp Chairperson and CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share, then sold 9,500 shares in multiple open-market trades at prices generally between about $530 and $548 per share. These transactions on March 10, 2026 were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is designed to execute trades automatically over time. Following the sales, she holds 130 shares directly and also has substantial indirect holdings through family trusts, including 324,518 shares held by a trust.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 9,500 shares ($5,127,273)
Net Sell
24 txns
Insider
ROTHBLATT MARTINE A
Role
Chairperson & CEO
Sold
9,500 shs ($5.13M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 9,500 | $0.00 | -- |
| Exercise | Common Stock | 9,500 | $146.03 | $1.39M |
| Sale | Common Stock | 800 | $530.03 | $424K |
| Sale | Common Stock | 120 | $530.4867 | $64K |
| Sale | Common Stock | 40 | $531.54 | $21K |
| Sale | Common Stock | 40 | $533.23 | $21K |
| Sale | Common Stock | 1,320 | $535.0916 | $706K |
| Sale | Common Stock | 459 | $535.9897 | $246K |
| Sale | Common Stock | 647 | $537.9227 | $348K |
| Sale | Common Stock | 563 | $539.0224 | $303K |
| Sale | Common Stock | 1,351 | $539.839 | $729K |
| Sale | Common Stock | 440 | $540.6295 | $238K |
| Sale | Common Stock | 400 | $541.6902 | $217K |
| Sale | Common Stock | 560 | $542.8795 | $304K |
| Sale | Common Stock | 824 | $544.0414 | $448K |
| Sale | Common Stock | 936 | $545.0522 | $510K |
| Sale | Common Stock | 480 | $546.2075 | $262K |
| Sale | Common Stock | 400 | $547.1385 | $219K |
| Sale | Common Stock | 120 | $548.10 | $66K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option — 173,500 shares (Direct);
Common Stock — 9,630 shares (Direct);
Common Stock — 166 shares (Indirect, by Spouse)
Footnotes (1)
- This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. This transaction was executed in multiple trades at prices ranging from $541.43 to $542.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $542.54 to $543.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $543.59 to $544.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $544.705 to $545.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $545.72 to $546.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $546.835 to $547.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. This transaction was executed in multiple trades at prices ranging from $529.38 to $530.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $530.44 to $530.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $534.69 to $535.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $535.72 to $536.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $537.24 to $538.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $538.30 to $539.29. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $539.30 to $540.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $540.34 to $541.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
FAQ
What did United Therapeutics (UTHR) CEO Martine Rothblatt report in this Form 4?
Martine Rothblatt reported exercising options for 9,500 United Therapeutics shares at $146.03 and selling 9,500 shares in open-market trades around $530–$548 per share. The activity reflects an exercise-and-sell pattern rather than an open-market share purchase.
Was the United Therapeutics (UTHR) CEO’s stock sale part of a 10b5-1 plan?
Yes. The filing states the option exercise and resulting stock sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Such plans automate trades over time and reduce the significance of trade timing as a discretionary signal.
What type of insider transaction is shown for United Therapeutics (UTHR)?
The Form 4 shows an option exercise followed by open-market sales. Rothblatt exercised 9,500 stock options and sold 9,500 common shares in multiple trades. This is an exercise-and-sell pattern, converting option value into cash rather than an open-market share accumulation.
Over what period will the United Therapeutics (UTHR) CEO’s 10b5-1 plan remain in effect?
The 10b5-1 plan will continue until the earlier of two events: the exercise of 1,734,410 stock options that expire on March 17, 2027, or December 31, 2026. Future option exercises and sales may occur under this same plan.
Did the United Therapeutics (UTHR) Form 4 indicate multiple trade prices for the CEO’s stock sales?
Yes. Several sales were executed in multiple trades within specified price ranges, such as from $529.38 to $530.35 or from $546.835 to $547.50. The Form 4 reports weighted-average prices and offers to provide detailed trade breakdowns upon request.